

BYLAWS

INDEPENDENT CITIZEN’S OVERSIGHT COMMITTEE **(CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE)**

ARTICLE I: AUTHORITY

Section 1. The California Institute for Regenerative Medicine (the “Institute”) was established by the California Constitution. (California Constitution, article XXXV, section 1.)

Section 2. The Independent Citizen’s Oversight Committee (the “ICOC”) for the Institute was created by the California Stem Cell Research and Cures Act (Health & Safety Code section 125290.10 to section 125290.70), as amended by the California Stem Cell Research, Treatments, and Cures Act (Health & Safety Code section 125290.10 to section 125290.76) (the “Act”).

ARTICLE II: PURPOSES

Section 1. The purposes of the Institute are the following:

- (a) To make grants and loans for stem cell and genetic research, for research facilities, and for other vital research opportunities to realize therapies, protocols, and/or medical procedures that will result in, as speedily as possible, the cure for, and/or substantial mitigation of, major diseases, injuries, and orphan diseases.
- (b) To support all stages of the process of developing cures, from laboratory research through successful clinical trials to the delivery of treatments and cures.
- (c) To establish the appropriate regulatory standards and oversight bodies for research and facilities development.

(California Constitution, article XXXV, section 2; Health & Safety Code section 125290.40.)

Section 2. The purpose of the ICOC is to govern the Institute. (Health & Safety Code section 125290.15.)

ARTICLE III: FUNCTIONS

The ICOC shall perform, or delegate, the following functions:

- (a) Oversee the operations of the Institute.
- (b) Develop annual and long-term strategic research and financial plans for the institute.
- (c) Make final decisions on research standards and grant awards in California across the research and therapy development and delivery spectrum, from genetic and stem cell discovery research and early development to clinical trials and therapy delivery.
- (d) Ensure the completion of an annual financial audit of the Institute’s operations.

- (e) Issue public reports on the activities of the Institute.
- (f) Develop and implement programs to enhance patient access to affordable stem cell, genetic research, and related treatments and cures through public hospitals and clinics and establish policies regarding intellectual property rights arising from research funded by the institute.
- (g) Establish and oversee the Institute's research, therapy development, and therapy delivery programs, including but not limited to the Alpha Stem Cell Clinics and Community Care Centers of Excellence, training and fellowship, and shared research laboratory programs.
- (h) Establish and oversee the development of policies and programs to help make treatments and cures arising from Institute-funded research available and affordable for California patients, through engagement with healthcare providers, research and therapy development institutions, businesses, governmental agencies, philanthropists, foundations, and patient advocacy groups, and based on recommendations made by the Treatments and Cures Accessibility and Affordability Working Group.
- (i) Establish rules and guidelines for the operation of the ICOC and its working groups.
- (j) Perform all other acts necessary or appropriate in the exercise of its power, authority, and jurisdiction over the institute.
- (k) Select members of the working groups.
- (l) Adopt, amend, and rescind rules and regulations to carry out the purposes and provisions of this chapter, and to govern the procedures of the ICOC. Except as provided in subdivision (m), these rules and regulations shall be adopted in accordance with the Administrative Procedure Act (Government Code, Title 2, Division 3, Part 1, Chapter 3.5, Sections 11340 et seq.).
- (m) Notwithstanding the Administrative Procedure Act (APA), and in order to facilitate the immediate commencement of research covered by this chapter, the ICOC may adopt interim regulations without compliance with the procedures set forth in the APA. The interim regulations shall remain in effect for 270 days unless earlier superseded by regulations adopted pursuant to the APA. For purposes of subdivision (l), requests for applications, program announcements, and notices of award shall not be considered
- (n) Request the issuance of bonds from the California Stem Cell Research and Cures Finance Committee and loans from the Pooled Money Investment Board.
- (o) Modify, as it sees appropriate, its funding and finance programs to optimize the Institute's ability to achieve the objective that its activities be revenue-positive for the State of California during its first five years of operation without jeopardizing the progress of its core medical and scientific research program.

(p) Accept additional revenue and real and personal property, including, but not limited to, gifts, royalties, interest, and appropriations that may be used to supplement annual research grant funding and the operations of the Institute.

(q) Subject to the restrictions set forth in this article, develop conflict of interest standards, and at its discretion, consult with the National Academy of Sciences and the Scientific and Medical Accountability Standards Working Group, for the consideration of funding awards based on best practices established by the National Academies of Sciences to prevent conflicts of interest in the award of research funding and update those standards no less than every four years to be, at the ICOC's discretion, generally aligned with standards adopted by the National Academies of Sciences, subject to the constitutional and statutory requirements applicable to the institute.

(Health & Safety Code section 125290.40.)

ARTICLE IV: MEMBERS

Section 1. (Appointment) The ICOC shall have 35 members appointed as set forth in the Act. (Health & Safety Code section 125290.20, subdivision (a).). A short summary of persons making appointments, nominations and elections and the respective appointees is attached as Exhibit A to these Bylaws for reference.

Section 2. (Delegation of Authority) Any ICOC member who is an executive officer of a California university, a nonprofit research institution or life science commercial entity may from time to time delegate those duties to an executive officer of the entity or to the dean of the medical school, as applicable (an "alternate"). (Health & Safety Code section 125290.20(a), subdivision (2)D).) An ICOC member may not have more than one alternate at any one time.

Section 3. (Oath of Allegiance) Each ICOC member and alternate shall take the oath of allegiance required by the California Constitution. (California Constitution, article XX, section 3)

Section 4. (Conflict of Interest Code) The Act provides that the California Political Reform Act (the "PRA"; Government Code section 81000 through section 91014) shall apply to the Institute and to the ICOC except as provided in section 125290.30 of the Act and in subdivision (e) of section 125290.50 of the Act. (Health & Safety Code section 125290.30, subdivision (i).) The PRA requires state and local governmental agencies to adopt and promulgate conflict of interest codes. Each ICOC member and alternate shall file a statement of economic interest as required by any conflict of interest code adopted by the ICOC pursuant to the PRA.

Section 5. (Conflict of Interest Policy) Each ICOC member shall abide by the "Conflict of Interest Policy" adopted by the ICOC and attached as Exhibit B to these Bylaws.

Section 6. (Vacancies) If a vacancy occurs within a term and has not been filled in accordance with the Act, the ICOC shall proceed to operate with the remaining members, provided that at least 60 percent of the members have been appointed. (Health & Safety Code section 125290.20(b), subdivision (1).)

Section 7. (Expiration of Term) ICOC members whose terms have expired shall continue to serve until their replacements are appointed. (Health & Safety Code section 125290.20(c), subdivision (3).)

Section 8. (Compensation and Expenses) (a) As required in the Act, each member and alternate of the ICOC, except the Chairperson, Vice Chairperson, and Patient Advocate and Nurse members, shall receive a per diem of one hundred dollars (\$100) per day for each day actually spent in the discharge of the member's or alternate's duties, plus reasonable and necessary travel and other expenses incurred in the performance of the member's or alternate's duties. (Health & Safety Code section 125290.45, subdivision (b)(2).) Therefore, each member and alternate shall be paid \$100 for the following:

(1) Any day on which a member attends a meeting of the full ICOC, an ICOC subcommittee or an ICOC working group to which the member is appointed or performs an activity which has been pre-determined by the Chairperson as a discharge of the member's duties.

(2) Any day in which the member is engaged in additional activities that have been approved in advance by the Chairperson to be a discharge of the members' duties.

(b) Furthermore, each member and alternate, except the Chairperson, Vice Chairperson, and Patient Advocate and Nurse members, shall be paid \$12.50 per hour for time spent in preparation for a meeting of the full ICOC, an ICOC subcommittee, or an ICOC working group to which the member or alternate is appointed.

(c) The dollar amounts in subdivisions (a) and (b) shall be adjusted annually by multiplying them by a fraction, the denominator of which is the 2004 Annual Average, California Consumer Price Index - California, All Items (Los Angeles-Riverside-Orange County, San Francisco-Oakland-San Jose, San Diego (1982-84=100)) (the "Annual Index") as prepared by the Division of Labor Statistics and Research in the California Department of Industrial Relations and the numerator of which is the Annual Index published for each subsequent year in which the adjustment is to be computed and made. The daily rate shall be adjusted by multiplying the adjusted hourly rate by eight hours. The new daily and hourly per diems will become effective in the month following the month in which the Annual Index is published.

(d) In lieu of the per diem provided for in subdivisions (a) and (b), the Board shall establish a daily consulting rate for Patient Advocate and Nurse members for the time spent by Patient Advocate and Nurse members in preparation for, and participation in, Institute, working group, and ICOC meetings, including compensation and expense reimbursement for careqivers when necessary to facilitate a members participation in a meeting as a result of the members medical condition. (Health & Safety Code section 125290.20(c), subdivision (3).)

ARTICLE V: MEETINGS

Section 1. (Regular Meetings) The ICOC shall hold at least four public meetings per year. The ICOC may hold additional meetings, including virtual or telephonic meetings, as it determines are necessary or appropriate. (Health & Safety Code section 125290.30, subdivision (f)(1).) Members are strongly encouraged to attend meetings, except for telephonic meetings, in person.

Section 2. (Open and Closed Meetings) (a) All meetings of the ICOC, except those closed sessions described below or otherwise permitted by law, shall be open and public and in conformance with law. (Health & Safety Code section 125290.30(f).) In particular, all open meetings shall conform to the Bagley-Keene Open Meeting Act, including requirements for notice of meetings, preparation and distribution of agendas and written materials, inspection of public records, closed sessions and emergency meetings, maintenance of records, and disruption of a public meeting. The public shall be invited to comment upon each item on the agenda and each individual speaker so commenting may be required to limit their comments to as few as three minutes.

(b) The ICOC shall adopt all governance, scientific, medical, and regulatory standards in public meetings. (Health & Safety Code section 125290.30, subdivision (f)(2).)

(c) The ICOC, and its subcommittees, may conduct closed sessions as permitted by the Bagley-Keene Open Meeting Act. (Government Code section 11126.) In addition, the ICOC may conduct closed sessions when it meets to consider or discuss:

(1) Matters involving information relating to patients or medical subjects, the disclosure of which would constitute an unwarranted invasion of personal privacy.

(2) Matters involving confidential intellectual property or work product, whether patentable or not, including, but not limited to, any formula, plan, pattern, process, tool, mechanism, compound, procedure, production data, or compilation of information, which is not patented, which is known only to certain individuals who are using it to fabricate, produce, or compound an article of trade or a service having commercial value and which gives its user an opportunity to obtain a business advantage over competitors who do not know it or use it.

(3) Matters involving prepublication, confidential scientific research or data.

(4) Matters concerning the appointment, employment, performance, compensation, or dismissal of Institute officers and employees; however, action on compensation of the institute's officers and employees shall only be taken in open session.

Section 3. (Notice of Meetings) At least 10 days in advance of each regular meeting of the ICOC, notice of the meeting shall be given to any person or organization who requests that notice in writing and that it be made made available on the Internet. The notice shall include the name, address, and telephone number of any person who can provide further information prior to the meeting and a specific agenda for the meeting, containing a brief description of the items of business to be transacted or discussed in either open or closed session. The written notice shall additionally include the address of the Internet site where notices required by this article are made available and otherwise comply with the Bagley-Keene Open Meeting Act. If the agenda for any meeting includes consideration of any amendment to the "policy enhancements" adopted by the ICOC at its July 12, 2005, and August 5, 2005, meetings, notice of the meeting shall also be given to the President pro Tempore of the California Senate and the Speaker of the California Assembly at least 10 days in advance of the meeting.

Section 4. (Special and Emergency Meetings) Special and emergency meetings may be called by the Chair if compliance with the 10-day notice would impose a substantial hardship on the ICOC or if immediate action is required to protect the public interest. These meetings shall

conform to the requirements of the Bagley-Keene Open Meeting Act (Government Code section 11120 through section 11132) applicable to special and emergency meetings.

Section 5. (Quorum) A quorum of the ICOC or an ICOC subcommittee shall be at least sixty five percent (65%), respectively, of the ICOC members or members of an ICOC subcommittee who are eligible to vote. (Health & Safety Code section 125292.10, subdivision (s).)

Section 6. (Voting)

(a) All actions of the ICOC shall be taken at properly called meetings at which there is a quorum. Unless a greater number is required by the Act or these Bylaws, the ICOC shall act by a majority vote of a quorum. Amendments to pending motions may be made with the concurrence of the maker of the motion and the second, unless a member of the ICOC requests a vote on the proposed amendment, in which case, action on the proposed amendment shall be taken by a majority vote of all members present before the vote on the pending motion. Amendments to the “policy enhancements” adopted by the ICOC at its July 12, 2005, and August 5, 2005, meetings shall only be made by a vote of seventy percent (70%) of all members present.

(b) Provided that five or fewer members have a need to place their vote before the debate has concluded and provided that the Board has taken a sampling of public comment both for and against the motion at the instant meeting or at an earlier meeting, the Chair may open the roll to record the votes of members who have to leave a meeting under one or more of the following circumstances:

1. The Board has had a prior discussion regarding the matter under consideration and has had an opportunity to review written materials in advance of the meeting; or

2. It is critical to the agency’s mission for the Board to take action on the matter at the meeting and there will be another opportunity for the Board to revisit the matter in the future.

When the roll has been opened before debate has been completed, the Board shall take additional public comment before the roll call vote is concluded.

(c) In addition, the Chair may leave the roll open after debate has concluded in order to permit a member to participate in the vote.

Section 7. (Rules of Order) Debate and proceedings before the ICOC shall be conducted in accordance with Robert’s Rules of Order Newly Revised (10th Edition) except to the extent in conflict with the Act, these Bylaws, other rules of the ICOC or other statutory requirements.

Section 8. (Consent Calendar) A consent agenda may be presented by the Chair at the beginning of a meeting. Items may be removed from the consent agenda upon the request of any member. Items not removed may be adopted by general consent without debate. Removed items may be taken up either immediately after the consent agenda or later on the agenda at the discretion of the Chair of the Board.

ARTICLE VI: SUBCOMMITTEES

Section 1. (Establishment) The ICOC may establish subcommittees to facilitate the work of the board. The ICOC shall determine the size, mission, and jurisdiction of each subcommittee, including whether it exercises advisory or delegated power.

Section 2. (Members) The ICOC shall appoint the chairperson of each subcommittee based upon the recommendations of the members of the ICOC. The chairperson of the subcommittee shall then appoint the other members of the subcommittee with the concurrence of the Chairperson of the ICOC. Members of the ICOC may volunteer for service on subcommittees. If the ICOC reduces the size of a subcommittee, the ICOC shall determine the membership of the subcommittee.

Section 3. (Compensation and Expenses) Members of subcommittees, except the Chairperson, Vice Chairperson, and Patient Advocate and Nurse members, shall receive a per diem of one hundred dollars (\$100) per day (adjusted annually as set forth in Article IV, Section 7 above) for each day actually spent in the discharge of the member's duties, plus reasonable and necessary travel and other expenses incurred in the performance of the member's duties.

Section 4. (Governance Subcommittee) (a) The Governance Subcommittee reviews language and makes comments upon policies related to management of the ICOC and the Institute. The Subcommittee's corporate governance responsibilities involve (i) making recommendations on the Institute's compensation policy and contracting policies; (ii) working with the President to establish goals for the management of the Institute; (iii) monitoring the achievement of these goals in order to optimize performance; (iv) evaluating the performance of the Chair, Vice Chair, and President and making recommendations regarding their compensation to the ICOC; and (v) recommending a compensation policy for Patient Advocate and Nurse members for the time spent in preparation for, and participation in, institute, working group, and ICOC meetings. The Governance Subcommittee's recommendations shall be considered by the ICOC. The Governance Subcommittee shall make regular reports back to the ICOC, as appropriate.

(b) The Governance Subcommittee shall be composed of the Chairperson, a chairperson chosen by the ICOC and other ICOC members chosen by such chairperson based on nominations by the Chairperson and self-nomination by ICOC members. The Subcommittee shall be composed of ICOC members with experience and/or demonstrated interest in organizational management and expertise in human resources and financial oversight.

Section 5. (Application Review Subcommittee) (a) The Application Review Subcommittee shall be composed of the members of the Board appointed or elected pursuant to Health and Safety Code section 125290.20(a)(2)(C) and (a)(3)(7). The other members of the ICOC shall serve as ex officio members of the Subcommittee. The Subcommittee shall be chaired by the Chairperson of the ICOC, with the support of the Vice-Chair of the ICOC.

(b) The Subcommittee shall review the recommendations for funding that arise from the Scientific and Medical Research Funding Working Group (Grants Working Group) and the Scientific and Medical Research Facilities Working Group (Facilities Working Group) and shall make decisions on applications for funding in public meetings, provided, however, that the Subcommittee may meet in closed session to consider proprietary information relating to applications as permitted by Health and Safety Code section 125290.30(f).

- (c) In anticipation of the meeting of the Application Review Subcommittee at which funding decisions will be made, staff will provide the Subcommittee with the recommendation of the respective Working Group. In addition, staff will review the recommendations of the respective Working Group, make any additional recommendations they deem necessary, and present these recommendations to the Subcommittee at its meeting.
- (d) As part of its consideration of applications for funding, the Subcommittee shall consider:
 - (i) programmatic issues, with a focus on portfolio balance, relevance to unmet health need, urgency of timeline, alignment with focus of the Act, alignment with the goals and priorities of the Request for Applications, budget adjustments if necessary, and other stipulations; (ii) recommendations made by CIRM's staff based on their review of the respective Working Group's recommendations; and (iii) public comment.
- (e) The Subcommittee shall meet concurrently with the Board whenever applications for research funding are to be considered.
- (f) Because members of the Subcommittee will be entitled to a per diem as members of the Board, they shall not be entitled to a separate per diem as members of the Subcommittee.

ARTICLE VII: WORKING GROUPS

Section 1. (Establishment) The Institute has the following four separate scientific and medical working groups, which shall report to the President. (Health & Safety Code section 125290.50):

- (a) Scientific and Medical Research Funding Working Group.
- (b) Scientific and Medical Accountability Standards Working Group.
- (c) Scientific and Medical Research Facilities Working Group.
- (d) Treatments and Cures Accessibility and Affordability Working Group

Section 2. (Appointment of Members) (a) The ICOC shall appoint members of each working group by a majority vote of all members present. (Health & Safety Code section 125290.50, subdivision (b).)

(b) The Scientific and Medical Accountability Standards Working Group shall have 19 members as follows:

- (i) Five ICOC members from the 10 disease advocacy group members described in paragraphs (3), (4), (5), and (6) of subdivision (a) of section 125290.20 of the Health & Safety Code.
- (ii) Nine scientists and clinicians nationally recognized in the field of pluripotent and progenitor cell research.
- (iii) Four medical ethicists.
- (iv) The Chairperson of the ICOC.

(Health & Safety Code section 125290.55, subdivision (a).)

(c) The Scientific and Medical Research Funding Working Group shall have at least 23 members as follows:

- (i) Seven ICOC members from the 12 disease advocacy group members described in paragraphs (3), (4), (5), and (6) of subdivision (a) of section 125290.20 of the Health & Safety Code.
 - (ii) At least fifteen scientists nationally recognized in the field of stem cell research, genetic research, or other vital research opportunities, 15 of whom shall be designated to serve on each expert review panel.
 - (iii) The Chairperson of the ICOC.
(Health & Safety Code section 125290.60, subdivision (a).)
- (d) The Scientific and Medical Research Facilities Working Group shall have 11 members as follows:
- (i) Six members of the Scientific and Medical Research Funding Working Group.
 - (ii) Four real estate specialists. To be eligible to serve on the Scientific and Medical Research Facilities Working Group, a real estate specialist shall be a resident of California, shall be prohibited from receiving compensation from any construction or development entity providing specialized services for medical research facilities, and shall not provide real estate facilities brokerage services for any applicant for, or any funding by the Scientific and Medical Research Facilities Working Group and shall not receive compensation from any recipient of institute funding grants.
 - (iii) The Chairperson of the ICOC.
(Health & Safety Code section 125290.65, subdivision (a).)
- (e) The Treatments and Cures Accessibility and Affordability Working Group shall have 17 members as follows:
- (i) Five members of the ICOC (the “Governing Board”), with at least two of those members drawn from the appointments made pursuant to paragraphs (3), (4), (5) or (6) of subdivision (a) of Section 125290.20.
 - (ii) An individual who has private sector experience in innovative therapy medical coverage terms, qualifications, and the process for reimbursement, including, if possible, experience with coverage negotiations with private insurers, health management organizations, or corporate self-insurance health plans.
 - (iii) An expert or a highly knowledgeable individual with experience in federal therapy coverage, qualifications, and process for reimbursement, including, if possible, experience with the Centers for Medicare and Medicaid Services.
 - (iv) An expert or a highly knowledgeable individual with experience in California's public insurance program (Covered California), coverage, qualifications, and the process for reimbursement of innovative therapies.

- (v) Two representatives from hospitals in California that are participating in stem cell clinical trials or that are treating patients with Federal Drug Administration-approved stem cell or genetic therapies.
- (vi) A representative from a philanthropic organization who has experience assisting patients with clinical trial access and affordability, or with access to, and the affordability of, innovative therapies.
- (vii) Two representatives from patient advocacy organizations who have technical expertise or experience in coverage, qualifications, and the process for reimbursement of innovative therapies.
- (viii) A health care economist, with experience in advising or negotiating with private insurers, government insurers, or corporate self-insurance programs on coverage for innovative therapies or human trials, including experience in assisting hospitals and clinics in covering financial gaps in coverage of the direct and indirect costs of innovative therapies.
- (ix) A patient navigator with training and experience helping patients obtain financial support from private insurers, public support, or nonprofit support, and helping patients obtain social service support to facilitate their participation in Federal Drug Administration-approved human trials or their qualification for access and financial assistance for innovative therapies.
- (x) The chairperson and vice chairperson of the Governing Board.

(Health & Safety Code section 125290.75, subdivision (a).)

Section 3. (Meetings) The ICOC shall adopt rules, procedures and practices for each working group based on recommendations made by that working group. (Health & Safety Code section 125290.50, subdivision (d).)

Section 4. (Reimbursement) The ICOC shall establish daily consulting rates and expense reimbursement standards for the non-ICOC members of its working groups. (Health & Safety Code section 125290.45, subdivision (b)(3).)

Section 5. (Grounds for Removal of Members) Any member of the Scientific and Medical Accountability Standards Working Group, the Scientific and Medical Research Funding Working Group, Scientific and Medical Facilities Working Group, and the Treatments and Cures Accessibility and Affordability Working Group may be removed by the ICOC for cause. The grounds for removal are as follows:

- (a) An intentional violation or violations of the Working Group conflict of interest policy applicable to the member;
- (b) Two or more grossly negligent violations of the Working Group conflict of interest policy applicable to the member;

- (c) Consistent failure to perform the assigned duties of the Working Group member or unexcused absence from three consecutive Working Group meetings;
- (d) Violation of medical or ethical standards by the member in his or her professional capacity as determined by the appropriate research institution or the appropriate professional group;
- (e) In the case of a member of the Medical Research Funding Working Group, employment by an institution located in the State of California;
- (f) In the case of a member of the Medical Facilities Working Group, acceptance of a contract in his or her professional capacity that would create a conflict of interest under the Act and that cannot be avoided through the procedures and policies preventing actual conflict of interest at the Working Group; and
- (g) The conviction of a felony or act involving serious moral turpitude.

Section 6. (Procedure for Suspension of Members) The President of the CIRM may suspend a member of a Working Group based on any of the grounds enumerated above by giving the member written notice of his or her suspension, including the grounds for the suspension. The suspension shall remain in effect until it is terminated by the President, the member resigns from the Working Group, or the ICOC has considered the permanent removal of the member pursuant to Section 7.

Section 7. (Procedure for Removal of Members) The President of CIRM may recommend to the ICOC the removal of a Working Group member based on any of the grounds enumerated above. The President must inform the member in writing that he has requested that the ICOC consider removal of the member at least 10 days prior to the ICOC's consideration of the matter. The notice must include the grounds for the recommendation. The member may address the ICOC in writing or in person during the meeting of the ICOC at which the removal of the member is considered.

Section 8. (Procedure for Temporary Leave of Absence) The President of CIRM or the chairperson of a Working Group shall consider and may, at his or her discretion, grant requests, from working group members for temporary leaves of absence, not to exceed six months, due to family or personal illness, death of a loved one, or other extenuating circumstances.

ARTICLE VIII: OFFICERS AND DUTIES

Section 1. (Officers) The officers of the ICOC shall be the Chairperson and a Vice Chairperson elected pursuant to Health and Safety Code section 125290.20(a)(7).

Section 2. (Selection) (a) Whenever the office of the Chairperson or Vice Chairperson is vacant, the ICOC shall elect a Chairperson or Vice Chairperson, as the case may be, from the nominees made by the Constitutional Officers (described on the attached Exhibit A).

(b) If there are more than two nominees for the office of Chairperson or Vice Chairperson, the nominee who receives the votes of a majority of a quorum of the ICOC shall be elected. If no nominee receives the votes of a majority of a quorum of the ICOC, the ICOC shall vote again, but the second vote shall be limited to the two nominees who received the highest number of votes in the first round of voting. The provisions set forth in paragraph (c) shall apply under these circumstances.

(c) If there are two nominees for the office of Chairperson or Vice Chairperson, the nominee who receives the votes of a majority of a quorum of the ICOC shall be elected. If the two nominees receive an equal number of votes, the ICOC shall vote again after a short recess in an effort to break the tie. If the ICOC does not break the tie in the second vote, the matter shall be tabled until the next meeting of the ICOC.

(d) The Chairperson and Vice Chairperson shall each serve a term of six years and may be compensated as full or part time employees. (Health & Safety Code section 125290.20, subdivision (a)(7).)

Section 3. (Duties) (a) The Chairperson and Vice Chairperson shall perform the duties of their respective offices as set forth in the Act and such other duties as may be approved by the ICOC.

(b) The Chairperson's primary responsibilities are to preside over meetings of the ICOC and:

(i) To manage the ICOC agenda and work flow including all evaluations and approvals of scientific and medical working group grants, loans, facilities, and standards evaluations;

(ii) To supervise all annual reports and public accountability requirements;

(iii) To manage and optimize the institute's bond financing plans and funding cash flow plan;

(iv) To interface with the California Legislature, the United States Congress, the California health care system, and the California public;

(v) To optimize all financial leverage opportunities for the institute, including without limitation, generating matching or supplemental funds through collaborations with other states, nations, territories, or institutions;

(vi) To lead negotiations for intellectual property agreements, policies, and contract terms; and

(vii) To serve as a member of the Scientific and Medical Accountability Standards Working Group, the Scientific and Medical Research Facilities Working Group, the Treatments and Cures Accessibility and Affordability Working Group, and as an ex-officio member of the Scientific and Medical Research Funding Working Group.

(Health & Safety Code section 125290.45, subdivision (b)(1)(A).)

(c) The Vice Chairperson's primary responsibilities are to support the Chairperson in all duties and to carry out those duties in the Chairperson's absence and to serve as a member of the Treatments and Cures Accessibility and Affordability Working Group. (Health & Safety Code section 125290.45, subdivision (b)(1)(A).)

Section 4. (Compensation) The ICOC shall set compensation for the Chairperson and Vice Chairperson within the range of compensation levels for executive officers and scientific, medical, technical, and administrative staff of medical schools within the University of California system and the nonprofit academic and research institutions described in paragraph (2) of subdivision (a) of section 125290.20 of the Health & Safety Code and travel expense reimbursement rates and moving and relocation expense limits. (Health & Safety Code section 125290.45, subdivision (b)(4).)

Section 5. (Citizen’s Financial Accountability Oversight Committee) The Act establishes a Citizens’ Financial Accountability Oversight Committee (the “Oversight Committee”) chaired by the State Controller to review the annual financial audit, the State Controller’s report and evaluation of that audit, and the financial practices of the Institute. (Health & Safety Code section 125290.30 (e).). The Chairperson shall appoint a public member of the committee who shall serve at the pleasure of the Chairperson. (Government Code section 1301.)

Section 6. (California Stem Cell Research and Cures Finance Committee) The California Stem Cell Research and Cures Bond Act of 2004 (the “Bond Act”; Health & Safety Code section 125291.10 through section 125290.85) creates the California Stem Cell Research and Cures Finance Committee (the “Finance Committee”) solely for the purpose of authorizing the issuance and sale, pursuant to the State General Obligation Bond Law, of the bonds and interim debt authorized by the Bond Act. (Health & Safety Code section 125291.40, subdivision (a).) The California Stem Cell Research, Treatments, and Cures Bond Act of 2020 (“2020 Bond Act”; Health & Safety Code section 125291.90 through section 125291.165) authorizes the Finance Committee to act as the finance committee for the purpose of authorizing the issuance and sale, pursuant to the State General Obligation Bond Law, of the bonds and interim debt authorized by the 2020 Bond Act. The Chairperson shall serve on the Finance Committee and shall appoint two members of the ICOC or their alternates to serve on the Finance Committee who shall serve at the pleasure of the Chairperson. (Government Code section 1301.)

ARTICLE IX: ORGANIZATION OF INSTITUTE

Section 1. (President) The President shall serve as Chief Executive of the Institute and shall perform the duties of his or her office as set forth in the Act and such other duties as may be approved by the ICOC. The President’s primary responsibilities are set forth in Health & Safety Code section 125290.45, subdivision (b)(1)(B). The President shall be elected by the ICOC and serve as an ex-officio member of each of the Institute’s working groups.

Section 2. (Administrative Structure) The President shall recommend to the ICOC for its approval the organizational structure of the staff of the Institute.

Section 3. (Employee Compensation) The President shall establish compensation for CIRM employees subject to the compensation policy and budget approved by the ICOC. The ICOC shall set compensation for the president.

ARTICLE X: DEFINITIONS

As used in these Bylaws, and otherwise by the ICOC, the following terms have the following meanings:

“Eligible to vote” means the member has been appointed and has not been restricted from voting by recusal, conflict of interest or other legal reason as determined by legal counsel for the ICOC.

“Ex-officio member” means a person who is a member by virtue of his or her office or these Bylaws. Such member may attend and participate in meetings, provided that he or she does not have a conflict of interest, but such member may not make motions or vote. Such member shall not be counted in determining the number of members required for a quorum or whether a quorum is present at a meeting.

ARTICLE X: AMENDMENTS

These Bylaws may be amended or repealed by the ICOC at any duly-noticed regular or special meeting by a majority vote of all members present.

EXHIBIT A
Appointment, Nomination and Election of ICOC Members

Person Making Appointment	Appointee Criteria	Subtotal
<u>Chancellor of the University of California at:</u> San Francisco Davis San Diego Los Angeles Irvine Riverside UCSF Fresno/Clovis	Appoints one executive officer from the respective campus. An appointee from UCSF Fresno/Clovis may be a faculty member, physician/scientist, researcher, or executive officers.	7
<u>Constitutional Officer</u> Governor Lieutenant Governor Treasurer Controller	Each appoints one executive officer from each of the following categories: - A California university that is not one of five campuses of the University of California listed above. - A California nonprofit academic and research institution that is not a part of the University of California. - A California life science commercial entity	12
	The Governor and Lieutenant Governor each appoints one representative from each of three California regional, state, or national disease advocacy groups, and the Treasurer and the Controller each appoints one representative from each of two California regional, state, or national disease advocacy groups and one nurse with experience in clinical trial management or stem cell or genetic therapy delivery.	12
	Each nominates one person for Chairperson and one person for Vice Chairman of the ICOC, each person meeting the criteria of the Act. (Health & Safety Code section 125290.20(a)(6)(A).).	

Speaker of the Assembly	Appoints one representative of a California regional, state, or national mental health disease or mental health conditions advocacy group.	1
President Pro Tem	Appoints one representative of a California regional, state, or national HIV/AIDS disease advocacy group.	1
ICOC Members	Elect the Chairperson and Vice Chairperson of ICOC from the nominees made by the Constitutional Officers.	2
Total Members		35

EXHIBIT B
Conflict of Interest Policy for Members of
the Independent Citizen's Oversight Committee

In order to ensure that members of the Independent Citizens' Oversight Committee ("ICOC") act pursuant to the highest ethical standards and to avoid potential conflicts of interest, the ICOC hereby adopts the following Conflict of Interest Policy for members, including alternates, of the ICOC:

1. Members of the ICOC shall not apply for or receive salary support through grants, loans or contracts from the ICOC, nor shall they act as a Principal Investigator.¹
2. Members of the ICOC shall not make, participate in making, or in any way attempt to use their official position to influence a decision regarding a grant, loan, or contract with their employer.
3. Members of the ICOC shall not make, participate in making or in any way attempt to use their official position to influence a decision regarding a grant, loan, or contract that financially benefits the member or the entity he or she represents.
4. Members of the ICOC shall not make, participate in making or in any way attempt to use their official position to influence a decision if it is reasonably foreseeable that the decision will have a material financial effect, distinguishable from its effect on the public generally, on the member or his or her immediate family, or on one of the member's financial interests as defined in the Political Reform Act.
5. When a member of the ICOC is precluded from participating in a decision because he or she has a conflict of interest, the member shall recuse himself or herself from discussing and voting on the matter.
6. Members of the ICOC shall not receive or accept any gift from any person or entity who is doing business with, or seeking to do business with, the California Institute for Regenerative Medicine ("CIRM") under circumstances from which it reasonably could be substantiated that the gift was intended to influence the member's future official actions or to reward the member for past ones.
7. Members of the ICOC shall not receive or accept, directly or indirectly, any gift, including money, or any service, gratuity, favor, entertainment, hospitality, loan, or any other thing of value from a lobbyist who is registered to lobby the ICOC or CIRM.

¹ Senior academic officers (including, but not limited to, chancellors, presidents of institutions, deans, chairs of departments, executive officers of research institutions, and other similar positions), who, as part of their responsibilities, oversee and advise researchers in their institution or who sign off on grants, loans or contracts shall not be deemed to have a conflict of interest under this provision. Recusal, however, is required in this situation, under Proposition 71 and points 2, 3, 4 and 5.

8. Nothing in this Statement is intended to modify the express authorization in Health and Safety Code section 125290.30(g)(1)(B), which provides: “A member of the ICOC may participate in a decision to approve or award a grant, loan or contract to an entity for the purpose of research involving a disease from which a member of his or her immediate family suffers or in which the member has an interest as a representative of a disease advocacy organization.”

I have read and understand the Conflict of Interest Policy for Members of the ICOC and I certify that I will abide by it as long as I am a member of the ICOC.

Signature _____ Date _____

Print Name _____